PE20070425A1 - Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos - Google Patents

Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos

Info

Publication number
PE20070425A1
PE20070425A1 PE2006001025A PE2006001025A PE20070425A1 PE 20070425 A1 PE20070425 A1 PE 20070425A1 PE 2006001025 A PE2006001025 A PE 2006001025A PE 2006001025 A PE2006001025 A PE 2006001025A PE 20070425 A1 PE20070425 A1 PE 20070425A1
Authority
PE
Peru
Prior art keywords
acetate
formulation
weight
amount
bazedoxifeno
Prior art date
Application number
PE2006001025A
Other languages
English (en)
Inventor
Syed M Shah
Christopher R Diorio
Kadum A Ali
Eric C Ehrnsperger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070425A1 publication Critical patent/PE20070425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) ACIDO 1-[4-(2-AZEPAN-1-IL-ETOXI)-BENCIL]-2-(4-HIDROXIFENIL)-3-METIL-1H-INDOL-5-OL ACETICO (ACETATO DE BAZEDOXIFENO) COMO UNA FORMA POLIMORFICA CRISTALINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1% A 30% EN PESO DE LA FORMULACION; B) UN PRIMER RELLENO/ DILUYENTE TAL COMO AZUCARES, CELULOSA MICROCRISTALINA, ALMIDON, ENTRE OTROS, QUE SE ENCUENTRA EN UNA CANTIDAD DE 5% A 85% EN PESO DE LA FORMULACION; C) UN SEGUNDO RELLENO/ DILUYENTE TAL COMO LACTOSA QUE SE ENCUENTRA EN UNA CANTIDAD DE 5% A 85% EN PESO DE LA FORMULACION; D) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO QUE SE ENCUENTRA EN UNA CANTIDAD DE HASTA 15% EN PESO DE LA FORMULACION; E) UN AGENTE DESLIZANTE/ DESINTEGRANTE TAL COMO GLICOLATO SODICO DE ALMIDON QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,01% A 10% EN PESO DE LA FORMULACION; F) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,01% A 10% EN PESO DE LA FORMULACION. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE LA COMPOSICION. EL ACETATO DE BAZEDOXIFENO ES UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS SIENDO UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS POSTMENOPAUSICA
PE2006001025A 2005-08-24 2006-08-23 Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos PE20070425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24

Publications (1)

Publication Number Publication Date
PE20070425A1 true PE20070425A1 (es) 2007-07-02

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001025A PE20070425A1 (es) 2005-08-24 2006-08-23 Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos

Country Status (21)

Country Link
US (1) US7771744B2 (es)
EP (1) EP1919456A2 (es)
JP (2) JP2009506053A (es)
KR (2) KR101584674B1 (es)
CN (1) CN101304731B (es)
AR (1) AR056471A1 (es)
AU (1) AU2006283121A1 (es)
BR (1) BRPI0615341A2 (es)
CA (1) CA2620174A1 (es)
CR (1) CR9746A (es)
EC (1) ECSP088214A (es)
GT (1) GT200600383A (es)
IL (2) IL189648A (es)
MX (1) MX2008002484A (es)
NO (1) NO20080991L (es)
PE (1) PE20070425A1 (es)
RU (1) RU2417084C2 (es)
SV (1) SV2008002825A (es)
TW (1) TW200738281A (es)
WO (1) WO2007024961A2 (es)
ZA (1) ZA200801742B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048534A1 (es) * 2004-04-08 2006-05-03 Wyeth Corp Formulaciones de acetato de bazedoxifeno
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
MX2008012299A (es) * 2006-03-31 2008-11-18 Rubicon Res Private Ltd Tabletas de desintegracion oral.
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
EP2645994B1 (en) * 2010-11-30 2017-11-01 WisTa Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
CA3229700A1 (en) * 2021-08-23 2023-03-02 Jan Brabek Treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
US6063403A (en) * 1995-06-22 2000-05-16 Akzo Nobel N.V. Compressed dry-granulation desogestrel tablets
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
NZ537051A (en) * 2002-06-13 2007-11-30 Wyeth Corp Use of bazedoxifene in an extended dosage treatment regimen
SG149081A1 (en) 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
PE20060173A1 (es) * 2004-04-07 2006-04-12 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
KR20060135866A (ko) 2004-04-07 2006-12-29 와이어쓰 바제독시펜 아세테이트의 결정질 다형체
CN1938272A (zh) * 2004-04-07 2007-03-28 惠氏公司 巴泽多昔芬醋酸盐的结晶多晶型物
AR048534A1 (es) * 2004-04-08 2006-05-03 Wyeth Corp Formulaciones de acetato de bazedoxifeno
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof

Also Published As

Publication number Publication date
KR20080043853A (ko) 2008-05-19
JP2013209419A (ja) 2013-10-10
CN101304731A (zh) 2008-11-12
TW200738281A (en) 2007-10-16
SV2008002825A (es) 2008-06-30
CR9746A (es) 2008-08-21
ZA200801742B (en) 2010-10-27
KR20140088917A (ko) 2014-07-11
RU2008107580A (ru) 2009-09-27
IL189648A (en) 2014-07-31
ECSP088214A (es) 2008-03-26
MX2008002484A (es) 2008-04-07
IL189648A0 (en) 2008-08-07
KR101584674B1 (ko) 2016-01-13
AR056471A1 (es) 2007-10-10
US20070048374A1 (en) 2007-03-01
US7771744B2 (en) 2010-08-10
RU2417084C2 (ru) 2011-04-27
CN101304731B (zh) 2012-06-20
EP1919456A2 (en) 2008-05-14
BRPI0615341A2 (pt) 2011-05-17
WO2007024961A3 (en) 2007-06-28
AU2006283121A1 (en) 2007-03-01
JP2009506053A (ja) 2009-02-12
WO2007024961A2 (en) 2007-03-01
NO20080991L (no) 2008-05-15
IL233392A0 (en) 2014-08-31
IL233392A (en) 2017-02-28
CA2620174A1 (en) 2007-03-01
GT200600383A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
PE20070425A1 (es) Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos
ES2526555T3 (es) Composición fungicida y método para controlar enfermedades de plantas
PE20130227A1 (es) Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
CL2008000133A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
PE20110841A1 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
PE20150626A1 (es) Modificador del sabor dulce
NZ600210A (en) Substituted 4-aminocyclohexane derivatives
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20080117A1 (es) Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20160874A1 (es) Compuestos quimicos
PE20120797A1 (es) Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
ECSP10010160A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
JO2937B1 (en) Tight muscles of the peptide vascular tensioner receptor
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
CL2014001309A1 (es) Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.
NZ630488A (en) Piperidine derivatives for gpr119 agonist
WO2008050199A3 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
WO2009138847A3 (en) An improved process for the preparation of cefozopran
PE20142399A1 (es) Compuestos de pirazol como inhibidores de sglt1

Legal Events

Date Code Title Description
FX Voluntary withdrawal